De-simplifying treatment is acceptable and cost-saving, if a choice is offered
Injectable HIV treatment unlikely to be arriving soon in the global south
Cabotegravir long-acting PrEP out of reach for upper middle-income nations
Second-line treatment nearly nine times more expensive than first-line in upper-middle income countries
Just six injections a year can prevent HIV: here’s what it will take for the world to afford them
ViiV Healthcare to allow 90 countries to access generic versions of HIV prevention shot
South Africa could be among the last to rollout child-friendly dolutegravir
Voluntary licensing via the Medicines Patent Pool is saving hundreds of thousands of lives
Getting to 95-95-95: global use of HIV generics would result in large reductions in spending, new infections and deaths
